• Our Company
    • About Us
    • Management Team
    • Scientific Advisory Board
    • Culture and Values
  • Our Approach
    • Science of IRX-2
    • IRX-2 Clinical Results
  • Clinical Development
    • The INSPIRE Study
    • Opportunities
  • News & Publications
    • Latest News
    • Publications
  • Contact Us

News & Publications › Latest News  

Latest News

February 09, 2021
Brooklyn ImmunoTherapeutics Announces Initiation of Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast Cancer

August 13, 2020
NTN Buzztime, Inc. and Brooklyn ImmunoTherapeutics LLC Enter into Definitive Merger Agreement

March 2, 2020
2020 Head and Neck Cancers Symposium: Immune Restorative Agent May Boost Immunotherapy Response in Advanced Head and Neck Cancer

June 3, 2019
Brooklyn ImmunoTherapeutics Announces Presentation of Ongoing Investigator Sponsored Trial of IRX-2 Regimen Combined with Nivolumab in Recurrent/Metastatic Solid Tumors

April 8, 2019
New clinical trials to investigate combination immunotherapy for treating advanced cancers

November 10, 2018
Brooklyn ImmunoTherapeutics Announces Presentation of Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer

November 7, 2018
Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics

November 7, 2018
Brooklyn ImmunoTherapeutics Announces Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer Accepted for Oral Presentation at the 2018 Annual Meeting of the Society for Immunotherapy of Cancer

  • Site Map
© 2021 Brooklyn ImmunoTherapeutics